Analyst Ratings for Maravai LifeSciences
Analysts have provided the following ratings for Maravai LifeSciences (NASDAQ:MRVI) within the last quarter:
B of A Securities Downgrades Maravai LifeSciences to Neutral, Lowers Price Target to $17
B of A Securities analyst Michael Ryskin downgrades Maravai LifeSciences (NASDAQ:MRVI) from Buy to Neutral and lowers the price target from $32 to $17.
Maravai LifeSciences Q3 Adj. EPS $0.37 Beats $0.33 Estimate, Sales $191.26M Miss $195.10M Estimate
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.33 by 12.12 percent. This is a 15.91 percent decrease over earnings of $0.44 per share
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.